Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemReportar como inadecuado




Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Reference: Hjerrild, KA, Jin, J, Wright, KE et al., (2016). Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system. Scientific Reports, 6, Article: 30357.Citable link to this page:

 

Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system

Abstract: The Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has recently emerged as a leading candidate antigen against the blood-stage human malaria parasite. However it has proved challenging to identify a heterologous expression platform that can produce a soluble protein-based vaccine in a manner compliant with current Good Manufacturing Practice (cGMP). Here we report the production of full-length PfRH5 protein using a cGMP-compliant platform called ExpreS2, based on a Drosophila melanogaster Schneider 2 (S2) stable cell line system. Five sequence variants of PfRH5 were expressed that differed in terms of mutagenesis strategies to remove potential N-linked glycans. All variants bound the PfRH5 receptor basigin and were recognized by a panel of monoclonal antibodies. Analysis following immunization of rabbits identified quantitative and qualitative differences in terms of the functional IgG antibody response against the P. falciparum parasite. The antibodies induced by one protein variant were shown to be qualitatively similar to responses induced by other vaccine platforms. This work identifies Drosophila S2 cells as a clinically-relevant platform suited for the production of 'difficult-to-make' proteins from Plasmodium parasites, and identifies a PfRH5 sequence variant that can be used for clinical production of a non-glycosylated, soluble full-length protein vaccine immunogen.

Peer Review status:Peer reviewedPublication status:PublishedVersion:Publisher's verion Funder: Irish Aid   Funder: EVI   Funder: Medical Research Council   Funder: European Community   Notes:Copyright The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International License. The imagesor other third party material in this article are included in the article’s Creative Commons license,unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,users will need to obtain permission from the license holder to reproduce the material. To view a copy of thislicense, visit http://creativecommons.org/licenses/by/4.0/. This is the final version of the article. This is available online from Nature at: https://doi.org/10.1038/srep30357

Bibliographic Details

Publisher: Nature Publishing Group

Publisher Website: http://www.nature.com/

Journal: Scientific Reportssee more from them

Publication Website: http://www.nature.com/srep/index.html

Volume: 6

Extent: Article: 30357

Issue Date: 2016

pages:Article: 30357Identifiers

Urn: uuid:b447e5a9-295b-4b97-96b3-119ea648fcdb

Source identifier: 631751

Doi: https://doi.org/10.1038/srep30357

Issn: 2045-2322 Item Description

Type: Journal article;

Version: Publisher's verion Tiny URL: pubs:631751

Relationships





Autor: Hjerrild, KA - - - Jin, J - institutionUniversity of Oxford Oxford, MSD, NDM, Jenner Institute - - - Wright, KE - - - Brown, RE -

Fuente: https://ora.ox.ac.uk/objects/uuid:b447e5a9-295b-4b97-96b3-119ea648fcdb



DESCARGAR PDF




Documentos relacionados